Hepatocellular Carcinoma Non-resectable Clinical Trial
Official title:
Transcatheter Arterial Chemoembolization Combined With Sintilimab and Bevacizumab for Unresectable Intermediate and Advanced Hepatocellular Carcinoma: A Prospective Study
Verified date | September 2021 |
Source | Second Affiliated Hospital of Guangzhou Medical University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study is to evaluate the safety and efficacy of transcatheter arterial chemoembolization (TACE) combined with sintilimab and bevacizumab in patients with unresectable intermediate or advanced hepatocellular carcinoma (HCC).
Status | Active, not recruiting |
Enrollment | 36 |
Est. completion date | December 31, 2022 |
Est. primary completion date | June 30, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Intermediate or advanced (Barcelona Clinic Liver Cancer stage B or C) HCC with diagnosis confirmed by histology/cytology or clinically - Disease not amenable to curative therapies but amenable to TACE - At least one measurable untreated lesion - No prior systemic therapy for HCC - Child-Pugh score class 5-7 - Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 at enrollment - Adequate organ and hematologic function - Life expectancy of at least 3 months - For women of childbearing potential and for men: agreement to remain abstinent Exclusion Criteria: - Diagnosis of fibrolamellar HCC, sarcomatoid HCC, or mixed cholangiocarcinoma and HCC - Diffuse HCC - Portal vein tumor thrombus (PVTT) involves the main trunk and contralateral branch or upper mesenteric vein - Inferior vena cava tumor thrombus - Metastatic disease that involves major airways or blood vessels - Symptomatic, untreated or progressing central nervous system metastasis - Uncontrolled tumor-related pain - Patients who received prior systemic therapy, immunotherapy, TACE, transcatheter arterial radioembolization (TARE), transcatheter arterial embolization (TAE), hepatic arterial infusion chemotherapy (HAIC) or radiation therapy for HCC - Treatment with systemic immunostimulatory agents - Use of herbal therapies or traditional Chinese medicines with anti-cancer activity within 2 weeks - History of malignancy other than HCC within 5 years prior to screening, except for malignancies with a negligible risk of metastasis or death - Uncontrolled ascites, hydrothorax or pericardial effusion - Prior esophageal and/or gastric varices bleeding within 6 months prior to initiation of study treatment - Prior life-threatening blood loss or grade 3/4 gastrointestinal bleeding requiring blood infusion, endoscopic or surgical intervention within 3 months - Untreated or incompletely treated esophageal and/or gastric varices with bleeding or high-risk for bleeding - History of gastrointestinal (GI) perforation and/or fistula in the past 6 months - history of GI obstruction (including incomplete intestinal obstruction requiring parenteral nutrition), extensive bowel resection (partial colectomy or extensive small bowel resection, complicated by chronic diarrhea), Crohn's disease, ulcerative colitis or long-term chronic diarrhea - History of hepatic encephalopathy - History of organ and stem cell transplantation - Long-term daily treatment with a non-steroidal anti-inflammatory drug (NSAID) - Use of immunosuppressive drugs in the past 4 weeks, excluding the routes of topical glucocorticoids or physiological doses of systemic glucocorticoids (ie no more than 10 mg/day of prednisone or equivalent). Temporary use of glucocorticoids for dyspnea symptoms such as asthma and chronic obstructive pulmonary disease is allowed - History of idiopathic pulmonary fibrosis, interstitial pneumonia, drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis - Active tuberculosis - Active severe infection; use of antibiotics within 2 weeks prior to injection of sintilimab - Autoimmune disease or immune deficiency - Inadequately controlled hypertension; history of hypertensive crisis or hypertensive encephalopathy - Bleeding diathesis or significant coagulopathy - Serious, non-healing or dehiscing wound, active ulcer, or untreated bone fracture - underwent major surgery (craniotomy, thoracotomy or open surgery) within 4 weeks; non-recovery from side effects of these procedure - History of venous thromboembolism in the past 6 months, but implantable IV ports or catheter-derived thrombosis, superficial venous thrombosis, or thrombosis after conventional anticoagulant therapy are excluded - Current or recent use of aspirin or treatment with dipyramidole, ticlopidine, clopidogrel, or cilostazol - uncontrolled metabolic disorder, non-malignant organ or systemic disease or secondary carcinomatous reaction, with high medical risk and/or uncertainty of life expectancy evaluation - Other acute or chronic diseases, mental illness, or abnormal laboratory test results that may lead to the following outcomes: increase the risk of participating in study or study drug administration, or interfere with the interpretation of the study results and considered by investigator as "NOT" eligible to participate in this study - Female patients who are pregnancy or breastfeeding |
Country | Name | City | State |
---|---|---|---|
China | The Second Affiliated Hospital of Guangzhou Medical University | Guangzhou | Guangdong |
Lead Sponsor | Collaborator |
---|---|
Second Affiliated Hospital of Guangzhou Medical University |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Adverse Events (AEs) | Number of patients with AE, treatment-related AE (TRAE), immune-related AE (irAE), AE of special interest (AESI), serious adverse event (SAE), assessed by NCI CTCAE v5.0. | 24 months | |
Primary | Progression free survival (PFS) assessed by investigators according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 and immune-related RECIST (irRECIST). | The time from initiation of treatment until the first occurrence of disease progression or death from any cause, whichever occurs first. | 24 months | |
Secondary | Overall survival (OS) | The time from initiation of treatment until the date of death from any cause. | 24 months | |
Secondary | Objective response rate (ORR) assessed by investigators according to RECIST 1.1 and irRECIST. | The percentage of patients who had a best overall tumor response rating of complete response (CR) or partial response (PR). | 24 months | |
Secondary | Disease control rate (DCR) assessed by investigators according to RECIST 1.1 and irRECIST. | The percentage of patients who had a tumor response rating of CR, PR, or stable disease (SD). | 24 months | |
Secondary | Duration of response (DOR) assessed by investigators according to RECIST 1.1 and irRECIST. | The time from the first occurrence of a documented objective response to disease progression (PD) or death. | 24 months | |
Secondary | PFS assessed by investigators according to Modified RECIST (mRECIST). | The time from initiation of treatment until the first occurrence of disease progression or death from any cause, whichever occurs first. | 24 months | |
Secondary | ORR assessed by investigators according to mRECIST. | The percentage of patients who had a best overall tumor response rating of CR or PR. | 24 months | |
Secondary | DCR assessed by investigators according to mRECIST. | The percentage of patients who had a tumor response rating of CR, PR, or SD. | 24 months | |
Secondary | DOR assessed by investigators according to mRECIST. | The time from the first occurrence of a documented objective response to PD or death. | 24 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05953337 -
Radioembolization Trial Utilizing Eye90 Microspheres™ for the Treatment of Hepatocellular Carcinoma (HCC)
|
N/A | |
Not yet recruiting |
NCT03283956 -
Safety and Efficacy of dRug-ElutiNg beADs Trans-arterial chemoEmbolization for Hepatocellular Carcinoma in Taiwan
|
N/A | |
Recruiting |
NCT03652467 -
The Safety and Efficacy of Deferoxamine for Treating Unresectable Hepatocellular Carcinoma
|
Phase 1 | |
Recruiting |
NCT05031949 -
Hyperbaric Oxygen Therapy Combined Camrelizumab in Patients With Advanced/Metastatic Hepatocellular Carcinoma
|
Phase 1 | |
Completed |
NCT03533920 -
Clinical Trial to Evaluate the Efficacy and Safety of UNI-DEB for Unresectable Hepatocellular Carcinoma
|
N/A | |
Recruiting |
NCT05992220 -
Atezolizumab Plus Bevacizumab Alone or Combined With External Beam Radiotherapy for HCC With Macrovascular Invasion
|
Phase 2 | |
Not yet recruiting |
NCT05057104 -
Non-inferiority Study of Unresectable Hepatocelluar Carcinoma Receiving Stereotactic Radiotherapy Combined With Hepatic Arterial Chemoembolization Compared With Conversion Hepatectomy
|
||
Completed |
NCT04599790 -
TACE Combined With Lenvatinib and Sintilimab for Advanced HCC
|
Phase 2 | |
Completed |
NCT04599777 -
TACE Combined With Sorafenib and Tislelizumab for Advanced HCC
|
Phase 2 | |
Recruiting |
NCT02967887 -
Evaluation of Hepatic Arterial Infusion of Cisplatin and 5-FU in Biomarker Stratified HCC
|
Phase 2 | |
Recruiting |
NCT05608200 -
Lenvatinib+Sintilimab+TACE vs. Lenvatinib+TACE for Advanced HCC
|
Phase 3 | |
Recruiting |
NCT05608213 -
Lenvatinib Plus I-125 Seed Brachytherapy vs. Lenvatinib for TACE-refractory HCC
|
Phase 3 | |
Completed |
NCT04926376 -
Safety and Effectiveness of Eye90 Microspheres™ in the Treatment of Unresectable HCC and mCRC
|
N/A | |
Recruiting |
NCT06133062 -
Atezolizumab and Bevacizumab With Proton Radiotherapy for Unresectable Hepatocellular Carcinoma
|
Phase 2 | |
Completed |
NCT02989922 -
A Study to Evaluate SHR-1210 in Subjects With Advanced HCC
|
Phase 2 | |
Recruiting |
NCT04273100 -
PD-1 Monoclonal Antibody, Lenvatinib and TACE in the Treatment of HCC
|
Phase 2 | |
Completed |
NCT06408753 -
Plasma Biomarker in Predicting Response and Toxicity in HCC Patients Treated With Checkpoint Inhibitors With or Without SBRT
|
||
Withdrawn |
NCT03563170 -
QUILT-3.072: NANT Hepatocellular Carcinoma (HCC) Vaccine
|
Phase 1/Phase 2 | |
Recruiting |
NCT05390112 -
Cohort Study of Patients With Hepatocellular Carcinoma and Circulating Tumor DNA Monitoring of Chemoembolization
|
||
Recruiting |
NCT05713994 -
Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for Unresectable Hepatocellular Carcinoma
|